Liau L, Ashkan K, Tran DD et al. First results on survival from a large Phase III clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J. Transl. Med. 16,142 (2018) In this multicenter Phase III clinical trial, the authors presented an interim analysis of an autologous dendritic cell vaccine, DCVax-L, used in newly diagnosed glioblastoma, where close to 90% of participants received treatment due to crossover design. The results showed a mean overall survival (OS) of 23.1 months, with 2-and 3-year survival rates of 46.2 and 25.4%, respectively. This was higher in patients with methylated MGMT status (mOS 34.7 vs 19.8 months). DCVax was shown to be well tolerated and safe, with only 2.1% of patients experiencing serious adverse events. Dendritic cells are key regulators of immune tolerance and immunity and the results from this study are very encouraging and demonstrate the potential of immunotherapy.
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Tumor treating fields (TTF) is one novel glioblastoma (GBM) treatment that has shown survival benefit in large clinical trials.
This study is a multicenter open-label Phase III randomized controlled trial that showed TTF with maintenance temozolomide (TTF-TMZ) improves progression-free survival and OS in functionally independent adult patients with newly diagnosed supratentorial GBM after maximal safe resection and concomitant chemoradiation. A total of 695 patients were adequately randomized and stratified according to the extent of resection and MGMT status. Median progression free survival from randomization and median OS was 6.7 and 20.9 months in TTF-TMZ group and 4.0 and 16.0 months in the TMZ group. Concerns of tolerability were addressed with 75% of patients complying to treatment of more than 18 h each day.
TTF is a noninvasive therapy that can be used in combination with biotherapy and immunotherapy for better outcomes in GBM treatment. This Phase-I trial explores the therapeutic potential of the live-attenuated poliovirus type 1 (Sabin) vaccine, PVSRIPO, using a novel convection-enhanced intratumoral delivery technique. To stimulate antitumor immunity and overcome limitations of the blood-brain barrier, a catheter delivers the drug in 61 patients in both doseescalation and dose-expansion phases, matching patient data against historical controls under an external data and safety monitoring board. While overall survival in the treatment group reached only 12.5 months (cf. 11.3 months in the control group), a plateau of 21% was seen from 24 to 60 months, compared with 14 and 4% at 24 and 36 months in the control group, respectively. Patients with the IDH1 R132 mutation unfortunately showed no survival advantage. While there was an adverse event rate of 88%, only 17% of patients were found to sustain a serious adverse event.
The use of bevacizumab post-PVSRIPO infusion conferred a further survival benefit with a disease-free interval of up to 34.1 months and survival up to 70.4 months.
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